Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biosly
- Development stage
- Unknown
- Lead developer
- TOA Biopharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Biosly is a triple-strain probiotic combination product developed by TOA Biopharma. It contains three symbiotic bacterial strains: *Enterococcus faecalis*, *Clostridium butyricum*, and *Bacillus mesentericus*. These strains work synergistically to regulate intestinal flora and improve gastrointestinal symptoms such as functional constipation and constipation-predominant irritable bowel syndrome (IBS-C). *Enterococcus faecalis* produces lactic acid, *Clostridium butyricum* produces butyric acid (a key energy source for colonocytes), and *Bacillus mesentericus* promotes the growth of beneficial bacteria like Bifidobacteria. The product is available in various forms, including orally disintegrating (OD) tablets, and is often used in combination with other therapies like magnesium oxide to manage chronic constipation.
- Brand names
- BioslyBiosly combination OD tabletsBiosly combination tablets
- Other names
- triple-strain probioticBio-Three
02
Targets
HDAC7FFAR2FFAR3 (Free fatty acid receptor 3)HDAC3 (Histone Deacetylase 3)HCAR2 (Hydroxycarboxylic acid receptor 2)Intestinal microbiota composition and function
Beyond the preview
Go deeper on Biosly.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosly.